Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint Buys 18 Percent of Biofrontera for $1.8M, Expands Drug Pipeline

NEW YORK, July 14 (GenomeWeb News) - DNAPrint Genomics said yesterday that it had purchased an 18-percent share of Leverkusen, Germany-based Biofrontera for 1.5 million ($1.8 million), a prelude to the development of a new pharmaceutical pipeline for DNAPrint. 

 

DNAPrint said it will add two of Biofrontera's Phase II drugs to its stable for chronic uriticaria and actinic keratosis, called BF-Derm1 and 5-aminolevulonic acid, respectively, the company said. DNAPrint will also add "a series" of drugs that are in pre-clinical development, including a prophylactic migraine treatment, it said.

 

"The key goal of our pharmaceutical research is the development of test/drug combinations for helping to ensure efficacy with compatible patients," said Hector Gomez, DNAPrint's chief medical officer.

 

"Over the next several months we plan to expand our relationship with Biofrontera, especially in the drug development arena, and we plan to take advantage of each others' locations to help promote our respective products and services in each others' markets," said Richard Gabriel, president and CEO of DNAPrint.

 

Gabriel and Gomez will sit on the Biofrontera board of directors in connection with the transaction, the company said.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.